Nexvet Biopharma plc (NVET) Receives Coverage Optimism Rating of 0.21
News coverage about Nexvet Biopharma plc (NASDAQ:NVET) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nexvet Biopharma plc earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.4228414051063 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Nexvet Biopharma plc (NVET) opened at 6.72 on Friday. Nexvet Biopharma plc has a 12 month low of $2.75 and a 12 month high of $6.76. The firm has a 50-day moving average of $6.69 and a 200 day moving average of $5.26.
Several brokerages have issued reports on NVET. Zacks Investment Research upgraded shares of Nexvet Biopharma plc from a “sell” rating to a “hold” rating in a research report on Friday, April 21st. Credit Suisse Group cut shares of Nexvet Biopharma plc from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $6.72 in a research report on Monday, April 24th.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/nexvet-biopharma-plc-nvet-receiving-somewhat-favorable-news-coverage-analysis-shows-updated.html.
Nexvet Biopharma plc Company Profile
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.
Receive News & Stock Ratings for Nexvet Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma plc and related stocks with our FREE daily email newsletter.